Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BEBT-908 in relapsed or refractory indolent B-cell lymphomas
ChiCTR2100042779Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ifupinostat in follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL) and 2 more (4 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective response rate. Started Apr 2021; status: recruiting.
02
Drugs
ifupinostat
03
Conditions
follicular lymphoma (FL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Lymphoplasmacytic Lymphoma (LPL)Waldenström macroglobulinemia (WM)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on ChiCTR2100042779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042779.